ライフサイエンスコーパス: nontransplant

1 patients were included (79 transplanted, 202 nontransplanted).

2 d higher than reported in the literature for nontransplants.

3 Adult patients with cirrhosis who underwent nontransplant abdominal operations were identified from

4 compared outcomes of transplanted vs matched nontransplanted adults with severe IEIs.

5 Nontransplanted adults with severe respiratory disease o

6 (1.3+/-0.5 vs. 2.0+/-0.7 mg/dL, P=0.01) than nontransplanted amyloid patients.

7 idence is also available from studies in the nontransplant and relapsed settings.

8 Normal (nontransplanted) and diabetic Lewis rats transplanted wi

9 Nontransplanted animals served as control.

10 s in the transplanted group as compared with nontransplanted animals.

11 rase chain reaction (qPCR) were performed on nontransplanted aortas and grafts explanted 2 and 4 week

12 Nontransplant approaches for treating aCML have otherwis

13 Similar recordings were performed in nontransplant areas of the transplant-recipient eyes, an

14 : 10.8 +/-12.0 spikes/1.6 sec) compared with nontransplant areas of these recipient eyes (mean: 2.4 +

15 nd expressed levels of EAAT2/GLT1 similar to nontransplanted astrocytes.

16 mice transplanted with B6 marrow or control nontransplanted B6-E mice.

17 upporting their role as permanent therapy in nontransplant candidates are limited.

18 f frontline treatment in both transplant and nontransplant candidates.

19 the operating room, death determination by a nontransplant caregiver, and rapid aortic cannulation, l

20 , the 10-year cumulative incidence of sMN in nontransplanted cases was 11.6%.

21 eding over time between liver transplant and nontransplant centers (p = 0.26).

22 omes comparable between liver transplant and nontransplant centers.

23 crease risk for poor health outcomes in many nontransplant chronic disease populations, lung recipien

24 fter KT, compared with a large population of nontransplanted CKD patients and with low-risk control p

25 transplantation are comparable with those of nontransplanted CKD patients with similar levels of kidn

26 in the transplant setting (compared with the nontransplanted CKD population), and management recommen

27 17 cells are detectable in animal models and nontransplant clinical populations, evidence linking CMV

28 To provide the nontransplant clinician with a basic understanding of th

29 tality was higher in the transplant than the nontransplant cohort (relative risk [RR], 5.85; P < .000

30 The nontransplant cohort included 196 patients receiving hyd

31 8.1%/L.kg [14.0% to 22.7%/L.kg]) than in the nontransplanted cohort (n = 14; 11.8%/L.kg [8.8% to 12.9

32 ced in HoxB8 chimeras but not in irradiated, nontransplanted control animals.

33 ups of mouse donor kidneys were studied: (1) nontransplanted control kidneys; (2) donor kidneys subje

34 is in HoxB8 chimeras, but not in irradiated, nontransplanted control mice.

35 antly younger than the average age of 70 for nontransplanted control patients with renal neoplasms.

36 aris and M mulatta) were used as a diabetic, nontransplanted control.

37 smatched renal transplant recipients and 101 nontransplant controls in a four-stage study including m

38 After 10 years, 137 survivors and nontransplant controls, case-matched on age, sex, and ra

39 ere compared to 100 consecutive hospitalized nontransplant controls.

40 -19 between SOT recipients and their matched nontransplant controls.

41 rences of gait parameters when compared with nontransplanted controls (P<0.05).

42 eased immunostaining for C5b-9 compared with nontransplanted controls, confirming local complement ac

43 there was virtually no remyelination in the nontransplanted controls.

44 rs were significantly elevated compared with nontransplanted controls.

45 ients, 7 liver transplant recipients, and 10 nontransplanted controls.

46 nsplanted with normal islets or nondiabetic, nontransplanted controls.

47 cebo-controlled study of 260 nonneutropenic, nontransplanted, critically ill patients with ICU-acquir

48 NI (KT-CNI-SCC) or mTOR-i (KT-mTORi-SCC), 25 nontransplants developing SCC (NoKT-SCC) and 6 healthy c

49 als of the allografts were compared with the nontransplanted donor aorta.

50 lated using genetic variants associated with nontransplant eGFR, on posttransplant eGFR.

51 The INTrEPID (Investigation of Nontransplant-Eligible Patients Who Are Inotrope Depende

52 d with cardiovascular and renal morbidity in nontransplant epidemiological studies and clinical trial

53 icantly lower incidence of septic shock than nontransplant GNB (10.3% vs 30.7%, p = .03).

54 ere significantly lower in transplant GNB vs nontransplant GNB: IL-2 (median [IQR]: 7.1 pg/ml [7.1, 7

55 ere significantly lower in transplant GNB vs nontransplant GNB: IL-2 (median [IQR]: 7.1 pg/ml [7.1, 7

56 een the transplanted grafts and the assessed nontransplanted grafts were alanine transaminase levels

57 and ischemic heart disease compared with the nontransplant group (P < 0.05).

58 here were six ascertained mortalities in the nontransplant group and one death in the transplanted gr

59 days after islet infusion, compared with the nontransplanted group (P = 0.005 and <0.001, respectivel

60 tients with AT >/=40%, with one death in the nontransplanted group and no deaths in the transplanted

61 ation as well as total pancreatectomy alone (nontransplanted group).

62 atients and 26 months (range, 0.1-37) in the nontransplanted group.

63 del.' The observed actuarial survival in the nontransplanted groups was much better than anticipated

64 rcinoma (SCC) and basal cell carcinoma (BCC) nontransplant GWAS.

65 h a gene expression database obtained for 55 nontransplant HCV-infected and uninfected liver samples.

66 line compared with AS-treated allografts and nontransplanted heart controls.

67 ty gene expression arrays, and compared with nontransplanted hearts using the log-average ration (LAR

68 vBcl-2-treated hearts were no different from nontransplanted hearts.

69 Nontransplanted hemophilia A mice died within a few hour

70 vely similar to those previously observed in nontransplanted, immunized solid-tumor patients.

71 al industries in complement therapeutics for nontransplant indications and the understanding that the

72 s (atorvastatin and dasatinib), approved for nontransplant indications, could regulate specific CRM g

73 transcript levels in urine specimens from 41 nontransplant individuals, 11 with UTI and 30 without UT

74 presenting symptoms were similar to those of nontransplant individuals.

75 76 through 2014, and 10 age- and sex-matched nontransplanted individuals for each of the groups from

76 Germany, Switzerland, and Japan, as well as nontransplant isolates from both human immunodeficiency

77 g depicts early adaptations in the remaining nontransplanted kidney of donors after nephrectomy.

78 ADCT values in nontransplanted kidney of donors increased from a preexp

79 shortcomings of extrapolating data from the nontransplant literature.

80 epithelial cells (HBE) obtained from normal, nontransplanted lungs or from brushings of nonsmokers, h

81 b-C9), can cause acute pulmonary distress in nontransplanted lungs.

82 igher inflammatory responses in DCs than did nontransplanted lysates, suggesting DC-mediated response

83 It is often measured in nontransplant medical and surgical conditions but has on

84 allograft recipients, and it is observed in nontransplanted mice and after CD8 T cell depletion with

85 Nontransplanted mice and stromal-vascular fraction sampl

86 In septic, nontransplanted mice at 24 hours, Ppara mice had elevate

87 Separate groups of nontransplanted mice underwent cecal ligation and punctu

88 tests (compared with those of 7 nontreated, nontransplanted mice with streptozotocin-induced diabete

89 alloreactive T cells were similar to naive, nontransplanted mice.

90 th after allogenic SCT vs those treated with nontransplant modalities was 5.6 (95% CI, 1.7-19; P = .0

91 hemistry were similar among transplanted and nontransplanted MSUD patients.

92 compared with EBV (-) transplant (n=15), and nontransplant (n=13) livers.

93 PRS of nontransplant NMSC is predictive of case:control status

94 new cancers and cancer-specific mortality to nontransplanted Ontario children born in the same year.

95 ransfer of mature allogeneic NK cells in the nontransplant or transplant setting has been shown to be

96 HCV specimens compared with a few controls (nontransplant: P <.001; transplant: P =.001) and contras

97 contrasted to the weak staining of controls (nontransplant: P <.001; transplant: P =.001).

98 etected in HCV cases compared with controls (nontransplant: P <.001; transplant: P =.006), which corr

99 to the absent to weak staining of controls (nontransplant: P =.001; transplant: P =.009).

100 The acini of normal, nontransplanted, pancreas, control specimen were consist

101 hat of their 823 matched dialysis waitlisted nontransplanted partners (91.6%, 74.5%, and 55.5% vs. 88

102 isease caused by a Trichosporon species in a nontransplant patient with cystic fibrosis.

103 ars to be similar to what is observed in the nontransplant patient.

104 R was significantly higher compared with the nontransplant patients [SIRR 3.56 (95% confidence interv

105 ednisone) metabolism was determined in eight nontransplant patients and in transplant recipients rece

106 an estimate that has proved very accurate in nontransplant patients and that does not include race va

107 expected to have poorer outcomes compared to nontransplant patients because of immunosuppression and

108 t, transplant patients were matched 1:1 with nontransplant patients for the chemokine and cytokine an

109 Obesity in nontransplant patients has been associated with hyperten

110 y) was investigated in nearly 900 successive nontransplant patients undergoing coronary angiography.

111 In nontransplant patients with chronic hepatitis C virus (H

112 Compared to age- and sex-matched nontransplant patients with chronic liver disease and CO

113 e identified 2307 SOT recipients and 231 047 nontransplant patients with COVID-19.

114 Furthermore, although twin studies in nontransplant patients with NMSC suggest a low genetic c

115 as strains causing sporadic cases of PCP in nontransplant patients with or without HIV infection.

116 ial stages of the disease process, which, in nontransplant patients, occurs long before clinical pres

117 1.08-1.91)] after an EGS event compared with nontransplant patients, predominantly amongst lung trans

118 with an increased incidence of cirrhosis in nontransplant patients, the authors tested the hypothesi

119 nding the natural history of this disease in nontransplant patients, this does not hold true for the

120 mily is associated with altered NMSC risk in nontransplant patients, we examined allelism in GSTM1, G

121 ic load of HCV genomes between the post- and nontransplant patients, whereas serum titers in the form

122 factor for coronary artery disease (CAD) in nontransplant patients.

123 ors behaving more aggressively than those in nontransplant patients.

124 able safety and efficacy profile compared to nontransplant patients.

125 tabolism, and accelerated atherosclerosis in nontransplant patients.

126 severity of COVID-19 in SOT recipients with nontransplant patients.

127 of EGS conditions among SOTRs compared with nontransplant patients.

128 d between non-lung transplant recipients and nontransplant patients.

129 ased for transplant recipients compared with nontransplant patients.

130 d die following a severe sepsis episode than nontransplant patients.

131 significantly better survival compared with nontransplanted patients (17 deaths) (hazard ratio, 4.48

132 ical neoplasms were identified in 32/1325 of nontransplanted patients and 15/701 transplanted patient

133 Among nontransplanted patients at these centers, 2206 patients

134 A cohort of nontransplanted patients from the French Centre de Refer

135 rol group consisted of hospital autopsies on nontransplanted patients from the odd-numbered years, 19

136 Nontransplanted patients had an ongoing risk of severe e

137 portional hazards regression analysis of our nontransplanted patients identified serum bilirubin, ser

138 The observed actuarial survival of nontransplanted patients was compared with the expected

139 The nontransplanted patients were matched for birth decade,

140 e of 7 years (age range, 1.5-18.2 years) and nontransplanted patients with juvenile MLD born between

141 rospective observational study, we recruited nontransplanted patients with P-CID aged 1 to 16 years t

142 did not receive transplantation (hereafter, nontransplanted patients) with juvenile MLD.

143 Among the nontransplanted patients, 5-year survival after disease

144 ostic Scoring System (IPSS-R), developed for nontransplanted patients, also correlates with post-HCT

145 mproving the cardiovascular risk profiles of nontransplanted patients, but the health benefits and po

146 In the nontransplanted patients, HBeAg was initially detectable

147 Compared with T/NK-cell lymphomas of nontransplanted patients, overall survival of systemic T

148 15 (21%) and 6 (20%) of the transplanted and nontransplanted patients, respectively.

149 Compared with the nontransplanted patients, the transplanted patients were

150 Unlike sinus node dysfunction in nontransplanted patients, which typically worsens with t

151 d longer OS (P = .03) and DFS (P = .02) than nontransplanted patients.

152 ndirectly compared with historical series of nontransplanted patients.

153 hort of 148 T/NK-cell lymphomas diagnosed in nontransplanted patients.

154 and lower MRI severity scores compared with nontransplanted patients.

155 the sickest critically ill, nonneutropenic, nontransplanted patients.

156 In the nontransplant pediatric population, adenovirus infection

157 d outcome of bronchiolitis obliterans in the nontransplant, pediatric population.

158 nd stem cell (13%) recipients, compared with nontransplanted peers (4%; P < 0.01).

159 Nontransplant physicians need education about donor risk

160 with cytomegalovirus (CMV) infection in the nontransplant population and evidence of CMV infection i

161 same cutoffs for defining proteinuria in the nontransplant population are applied.

162 which predicted cardiovascular events in the nontransplant population, appears to have predictive val

163 Compared with a matched nontransplant population, the incidence ratios for MI an

164 were also predictors of restenosis as in the nontransplant population.

165 ter-defibrillator implantation are as in the nontransplant population.

166 crease drastically compared with the general nontransplant population.

167 d intrinsic acute kidney injury (AKI) in the nontransplant population.

168 etastatic RCC, recent landmark trials in the nontransplanted population demonstrate that immunotherap

169 An emerging risk factor for death in nontransplant populations is physiological age as determ

170 ort data from large cohort studies in normal nontransplant populations, which suggested a higher risk

171 idney transplantation and how it compares to nontransplant populations.

172 proteins measured were higher than in normal nontransplant populations.

173 er cardiovascular morbidity and mortality in nontransplant populations.

174 etes, cardiovascular morbidity, and death in nontransplanted populations, which may help us to unders

175 In the nontransplanted primates given the same immunosuppressio

176 raphic and histologic findings that occur in nontransplant PSC patients.

177 o reverse the perfusion deficits observed in nontransplanted pumped human kidneys.

178 In nontransplanted pwCF, risk factors for severity included

179 8 +/- 7.9 mumol/L vs 17.5 +/- 5.1 mumol/L in nontransplant Rag mice, P < 0.05).

180 esponses were never recorded in age-matched, nontransplanted RCS rats.

181 recipients (GNB n = 29; SAB n = 26) and 225 nontransplant recipients (GNB n = 114; SAB n = 111) were

182 pients who developed NSCLC had worse OS than nontransplant recipients due to competing risks of death

183 All nonneutropenic, nontransplant recipients managed in five intensive care

184 differ significantly between transplant and nontransplant recipients with GNB (10.3% vs 15.8%, p = .

185 studies with CNIs, and the usage of CNIs in nontransplant recipients.

186 in transplant recipients to immunocompetent, nontransplant recipients.

187 fracture incidence in recipients compared to nontransplant reference groups matched on age, sex, and

188 1990 and 2020 was compared with a cohort of nontransplant related biopsies not requiring VA-ECMO.

189 ted (RANTES) was higher in transplant SAB vs nontransplant SAB (mean [SD]: 750.2 pg/ml [194.6] vs 656

190 detected in the plasma of lung transplant or nontransplant sepsis patients.

191 cribed after exposure to chemotherapy in the nontransplant setting and can also be a complication aft

192 ciation studies (GWAS) of NMSC in a general, nontransplant setting, can predict risk of, and time to

193 lished as standard of therapy for MDS in the nontransplant setting, the role of these agents in patie

194 ve of response to antiviral treatment in the nontransplant setting.

195 tumor-free survival than vaccination in the nontransplant setting.

196 reducing leukemia burden before HSCT and in nontransplant settings requires further studies.

197 (AML), immunotherapies have been explored in nontransplant settings.

198 ding applications in transplant and relevant nontransplant settings.

199 A subset of patients with nontransplant short-TL are at increased risk for bone ma

200 onflicted with the knowledge and practice of nontransplant specialists.

201 areful evaluation of the available effective nontransplant strategies.

202 A large number of nontransplant studies have, however, reported an associa

203 re than 10 years of follow-up and 94 healthy nontransplanted subjects as controls.

204 To evaluate the efficacy of nontransplant surgery for pediatric cholestasis, 58 clin

205 er transplantation versus medical therapy or nontransplant surgery, as well as early screening for HC

206 This was a multicenter analysis of nontransplant surgical approaches to intrahepatic choles

207 ence of varices accompanied by endoscopic or nontransplant surgical intervention.

208 Nontransplant surgical interventions are important adjun

209 SRSB is a nontransplant surgical option for patients with SBS who

210 ner with an understanding of the spectrum of nontransplant surgical options for managing patients wit

211 nts with a diagnosis of cirrhosis undergoing nontransplant surgical procedures between January 1, 199

212 ality for patients with cirrhosis undergoing nontransplant surgical procedures.

213 after chemotherapy through aggressive use of nontransplant surgical procedures.

214 ant regardless of the model used to estimate nontransplant survival.

215 In cohort A (nontransplant), SVR12 was achieved by 86%-89% of patient

216 At the same time, continuously evolving nontransplant therapies and transplant technologies mand

217 sease status, donor selection, and effective nontransplant therapies.

218 une diversification following transplant and nontransplant therapies.

219 vival may result from earlier, low-intensity nontransplant therapy, and aggressive pursuit of reduced

220 Patients at low risk should receive nontransplant therapy, whereas individual counseling is

221 en, including both liver transplantation and nontransplant treatment options.

222 are to discuss standard and investigational nontransplant treatment strategies for acute myeloid leu

223 likely to respond, at least transiently, to nontransplant treatment.

224 ons of QOL outcomes after BMT or alternative nontransplant treatments are appearing in the literature

225 (K) transplanted type-1 diabetics (n=5), and nontransplanted type-1 diabetics (n=12) served as contro

226 Serving as a control were 49 age-matched nontransplanted uteri.

227 Compared with a cohort of post-OLT and nontransplanted viremic HCV patients, the index patient

228 siblings at birth 1:10 with children born to nontransplanted women identified in the Danish general p